MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
Chemotherapy resistance in recurrent gliomas is a large hurdle for successful therapy. Here, the authors show that some recurrent gliomas harbour O-6-methylguanine-DNA methyltransferase (MGMT) genomic rearrangements, and in vitro and in vivo these contribute to temozolomide resistance.
Guardado en:
Autores principales: | Barbara Oldrini, Nuria Vaquero-Siguero, Quanhua Mu, Paula Kroon, Ying Zhang, Marcos Galán-Ganga, Zhaoshi Bao, Zheng Wang, Hanjie Liu, Jason K. Sa, Junfei Zhao, Hoon Kim, Sandra Rodriguez-Perales, Do-Hyun Nam, Roel G. W. Verhaak, Raul Rabadan, Tao Jiang, Jiguang Wang, Massimo Squatrito |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7b8914f315a045a59cf1cda9e3456735 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
por: Simone Kreth, et al.
Publicado: (2011) -
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)
por: Arshad A. Pandith, et al.
Publicado: (2018) -
Perfusion CT detects alterations in local cerebral flow of glioma related to IDH, MGMT and TERT status
por: Ke Wang, et al.
Publicado: (2021) -
A Prospective Clinical Study on MGMT Protein Expression and the Effect of Gene Promoter Methylation on Sensitivity to Chemotherapeutics in Spinal Glioma
por: Sun P, et al.
Publicado: (2021) -
MIND MGMT: Paranoid Nightmares of a Fugitive Reality.
por: Pepe Rojo
Publicado: (2017)